BTIG Reiterates Buy Rating on Liquidia Corporation
BTIG maintains its buy rating on Liquidia Corporation with a new price target of $109, a 48.34% upside from the current price.
Key Points
- BTIG reiterated its buy rating for Liquidia Corporation (LQDA) with a price target of $109 on June 22, 2026.
- BTIG's $109 price target implies 48.34% upside from Liquidia Corporation's ($LQDA) current $73.48 share price.
- Liquidia Corporation shares traded at about $71.07 on Monday, boasting a market cap of approximately $6.32 billion.
- Insider buying activity included multiple directors purchasing 5,882 shares each on June 16, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG has reiterated its buy rating on Liquidia Corporation (NasdaqCM: LQDA) with a price target of $109. This update from analyst Julian Harrison was announced on June 22, 2026. Liquidia's stock was trading around $71.07 on Monday.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Liquidia Corporation
Several institutional investors have made recent moves in Liquidia Corporation. Farallon Capital Management LLC and Caligan Partners LP maintained their positions with 8,656,038 and 8,118,892 shares respectively. BlackRock, Inc. slightly increased its holdings by 781 shares, ending with 5,489,144 shares valued at approximately $207.2 million. Findell Capital Management LLC boosted its stake by 650,663 shares, a 22.8% increase, bringing its total to 3,502,112 shares worth about $132.2 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 2,926,945 shares valued at $110.5 million.
Liquidia Corporation Stock Up 8.6%
Shares of Liquidia Corporation (NasdaqCM: LQDA) traded near $71.07 on Monday. The company has a market cap of $6.32 billion, a P/E ratio of 418.06, and a forward P/E of 12.75. Its beta is 0.593, indicating less volatility compared to the market. The stock's 52-week range is $11.85 to $73.22, with a 50-day moving average of $51.99 and a 200-day moving average of $36.90. Liquidia maintains a current ratio of 2.224 and a quick ratio of 1.983, with a debt-to-equity ratio of 170.221.
$LQDA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Liquidia reported revenue of $288.06 million, reflecting a 41.59% growth. The company achieved an EPS of $0.17, with a net margin of 7.74% and a return on equity of 28.18%. Its next earnings report is expected on August 12, 2026.
Insider Buying and Selling at Liquidia Corporation
Several insiders purchased shares of Liquidia Corporation on June 16, 2026. Stephen Bloch, Katherine Rielly-Gauvin, Paul Manning, Joanna Horobin, David Edward Johnson, and Damian Degoia each bought 5,882 shares.
Analysts Set New Price Targets
On June 22, 2026, BTIG maintained its buy rating on Liquidia Corporation with a $109 price target. HC Wainwright & Co. also reiterated a buy rating on June 5, 2026, with a target of $75. The consensus among analysts is a buy rating, with a mean target price of $66.13 based on 8 opinions.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina. It focuses on developing, manufacturing, and commercializing products for rare cardiopulmonary diseases. The company's main product candidates include YUTREPIA, an inhaled dry powder formulation for treating pulmonary arterial hypertension, and Remodulin, a treprostinil injection. Liquidia also develops L606, a liposomal formulation currently in phase III trials. Founded in 2004, the company employs 216 people under the leadership of CEO Dr. Roger A. Jeffs.
Bottom Line
BTIG's reiteration of a buy rating for Liquidia Corporation, along with a new target price, highlights continued confidence in the company's prospects. As a biopharmaceutical firm focused on rare diseases, Liquidia's stock performance and insider activity are closely watched by investors. Remember, analyst ratings and 13F filings reflect past data and might not indicate current or future performance.
Get Liquidia Corporation alerts
New 13F filings, insider trades, and analyst moves on $LQDA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.